Tenaya Therapeutics, Inc.

NASDAQ:TNYA

Biotechnology

Healthcare
$0.31 -0.58%

-$0.00 today

Market cap
$69.95M
Beta
2.82
P/E (TTM)
-1.3
EPS (TTM)
-$0.54
52W Low $0.53High $2.35

Volume 2.77M

Average 3.79M

TNYA Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Tenaya Therapeutics, Inc.NASDAQ: TNYA

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow turns negative

Q1 FY2026 financing cash flow was -$415K, compared with $50.26M a year earlier. Trailing-twelve-month financing cash flow was $57.73M. Over 3 fiscal years it compounded at +11.7% a year.

Context

  • Financing cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly financing cash flow holds near -$415K or moves back toward the trailing-twelve-month quarterly average of $14.43M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$415K-100.7% QoQ
Last fiscal yearDec 2025
$108.41M+127.0% YoY
LTMMar 2026
$57.73M+12.7% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.8%——
1 year+127.0%——
3-year CAGR+11.7%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
108.41M USD
Year-over-year change
+127.0%
4-year CAGR
-15.1%

Financing Cash Flow vs competitors

How TNYA compares with its peers on the latest reported figures

  • TNYA's LTM Mar 2026 financing cash flow of $57.73M is the 2nd largest of the 11 companies compared; the peer median is $20.86M.
  • Its year-over-year change of +12.7% is the 7th highest of 11, against a peer median of +45.8%.
  • Financing cash flow amounts to 25658.2% of revenue for TNYA, versus a peer median of 90.1%.
TNYA Competitors Peer median
Financing Cash Flow for TNYA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMRXImmuneering CorporationLTM Mar 2026$212.95M +1074.3%+2184.5%—
TNYATenaya Therapeutics, Inc.LTM Mar 2026$57.73M +12.7%+11.7%25658.2%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$50.66M -51.5%-16.6%179.5%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$42.1M +263.6%—60.8%
HUMAHumacyte, Inc.LTM Mar 2026$38.07M -61.2%—1888.3%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$24.66M +9371.4%+212.3%147.5%
ABEOAbeona Therapeutics Inc.LTM Mar 2026$17.05M -80.1%-15.5%117.3%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$7.05M +49.8%+31.2%62.9%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$4.07M +227.6%-9.7%11.1%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$1.3M +41.9%-27.5%—
PYXSPyxis Oncology, Inc.LTM Mar 2026$569K -68.7%+48.1%4.1%
Peer median (excluding TNYA) $20.86M+45.8%+10.7%90.1%

Competitors are the stored peer set for TNYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(72.72M)(123.67M)(124.08M)(111.13M)(90.6M)
Depreciation & Amortization2.96M6.47M8.69M8.47M8.85M
Deferred Income Tax00000
Stock-Based Compensation2.95M11.47M15.31M16.5M13.05M
Change in Working Capital4.74M(849K)(5.65M)(7.93M)(2.46M)
Accounts Receivables00000
Inventory00000
Accounts Payables8.6M1.66M(3.28M)(581K)(1.43M)
Other Working Capital(3.86M)(2.51M)(2.37M)(7.35M)(1.03M)
Other Non-Cash Items1.26M2.16M3.66M3.59M2.9M
Operating Cash Flow(60.81M)(104.42M)(102.07M)(90.5M)(68.26M)
Capital Expenditures(25.12M)(20.63M)(1.24M)(1.03M)(618K)
Acquisitions (Net)00000
Purchases of Investments(213.44M)(140.48M)(56.64M)(87.07M)0
Sales of Investments0244.75M106.62M89.21M56.7M
Other Investing Activities08K(25K)17K0
Investing Cash Flow(238.56M)83.65M48.72M1.13M56.08M
Debt Repayment00000
Common Stock Issued188.54M77.39M3.87M46.76M108.41M
Common Stock Repurchased(13K)0000
Dividends Paid00000
Other Financing Activities461K380K181K987K0
Financing Cash Flow208.97M77.77M4.05M47.75M108.41M
Effect of Forex Changes00000
Net Change in Cash(90.41M)57M(49.31M)(41.62M)96.22M
Free Cash Flow(85.93M)(125.05M)(103.31M)(91.53M)(68.88M)

Tenaya Therapeutics, Inc.

NASDAQ:TNYA

Intrinsic Alpha fair value

Locked

Current Price

$0.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.